Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of PDE4. Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic 3′,5′-adenosine monophosphate [cyclic AMP] metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP. The specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.

ZORYVE cream is a phosphodiesterase 4 inhibitor:

• ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. 
• ZORYVE cream, 0.15%, is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

• Apply ZORYVE cream:
  • 0.3%, once daily to affected areas of plaque psoriasis.
  • 0.15%, once daily to affected areas of mild to moderate atopic dermatitis.
• For topical use only.
• Not for ophthalmic, oral, or intravaginal use.

The most common adverse reactions (reported in ≥1% of subjects) are:

• Plaque Psoriasis: diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infections, and urinary tract infections. 
• Atopic Dermatitis: headache, nausea, application site pain, diarrhea, and vomiting.

Moderate to severe liver impairment (Child-Pugh B or C).

N/A